Zeljko Reiner


Affiliation: University Hospital Center
Country: Croatia


  1. Reiner Å, De Bacquer D, Kotseva K, Prugger C, De Backer G, Wood D. Treatment potential for dyslipidaemia management in patients with coronary heart disease across Europe: findings from the EUROASPIRE III survey. Atherosclerosis. 2013;231:300-7 pubmed publisher
    ..Therefore, a considerable potential still exists throughout Europe to reduce CHD mortality and morbidity rates through better treatment of dyslipidaemia. ..
  2. Mazalin Protulipac J, Sonicki Z, Reiner Å. Cardiovascular disease (CVD) risk factors in older adults - Perception and reality. Arch Gerontol Geriatr. 2015;61:88-92 pubmed publisher
    ..The results suggest insufficient awareness of CVD risk factors among Croatian older adults and a need for improved promotion of CVD prevention in this population segment. ..
  3. Reiner Å. PCSK9 inhibitors--past, present and future. Expert Opin Drug Metab Toxicol. 2015;11:1517-21 pubmed publisher
    ..Their use in statin-intolerant patients also raises questions, as the criteria for statin-intolerance are neither clear nor generally accepted. The presumed high cost of PCSK9 inhibitors might be an obstacle for their broader use. ..
  4. Gyberg V, De Bacquer D, De Backer G, Jennings C, Kotseva K, Mellbin L, et al. Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology. Cardiovasc Diabetol. 2015;14:133 pubmed publisher
    ..Despite advances in patient management there is further potential to improve both the detection and management of patients with diabetes and coronary artery disease. ..
  5. Sahebkar A, Simental Mendia L, Mikhailidis D, Pirro M, Banach M, Sirtori C, et al. Effect of statin therapy on plasma apolipoprotein CIII concentrations: A systematic review and meta-analysis of randomized controlled trials. J Clin Lipidol. 2018;12:801-809 pubmed publisher
    ..52 to -0.84, P = .004; I2: 0%), and lovastatin (WMD: -1.64, 95% CI: -2.22 to -1.07, P < .001; I2: 0%). This meta-analysis suggests that statin treatment significantly reduces plasma Apo CIII levels. ..
  6. Reiner Z. Statins in the primary prevention of cardiovascular disease. Nat Rev Cardiol. 2013;10:453-64 pubmed publisher
    ..In appropriately selected individuals, statins should also be used for primary prevention of ischaemic stroke and transient ischaemic attack. ..
  7. Reiner Å, De Backer G, Fras Z, Kotseva K, Tokgözoglu L, Wood D, et al. Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries--Findings from the EUROASPIRE IV survey. Atherosclerosis. 2016;246:243-50 pubmed publisher
  8. Reiner Z, Catapano A, De Backer G, Graham I, Taskinen M, Wiklund O, et al. [ESC/EAS Guidelines for the management of dyslipidaemias]. Rev Esp Cardiol. 2011;64:1168.e1-1168.e60 pubmed publisher
  9. Reiner Z. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update. Nutr Metab Cardiovasc Dis. 2013;23:799-807 pubmed publisher

More Information


  1. Pećin I, Reiner Å. Alirocumab: targeting PCSK9 to treat hypercholesterolemia. Drugs Today (Barc). 2015;51:681-7 pubmed publisher
    ..This review focuses on alirocumab, discussing currently available hard evidence on the beneficial effects of this drug in the treatment of hypercholesterolemia. ..